Rigel Pharmaceuticals Inc
RIGL22.450USD
+0.540+2.46%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
401.11MMarktkapitalisierung
10.79KGV TTM
mehr Informationen über Rigel Pharmaceuticals Inc Unternehmen
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Unternehmensinformationen
BörsenkürzelRIGL
Name des UnternehmensRigel Pharmaceuticals Inc
IPO-datumNov 29, 2000
CEOMr. Raul R. Rodriguez
Anzahl der mitarbeiter162
WertpapierartOrdinary Share
GeschäftsjahresendeNov 29
Addresse- -
Stadt- -
BörseNASDAQ Global Select Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelRIGL
IPO-datumNov 29, 2000
CEOMr. Raul R. Rodriguez
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
+36.36%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
8.48%
Morgan Stanley & Co. LLC
8.28%
BlackRock Institutional Trust Company, N.A.
8.23%
Soleus Capital Management, L.P.
6.33%
The Vanguard Group, Inc.
5.75%
Other
62.92%
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
8.48%
Morgan Stanley & Co. LLC
8.28%
BlackRock Institutional Trust Company, N.A.
8.23%
Soleus Capital Management, L.P.
6.33%
The Vanguard Group, Inc.
5.75%
Other
62.92%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
28.57%
Investment Advisor/Hedge Fund
20.61%
Hedge Fund
18.26%
Research Firm
9.88%
Individual Investor
2.66%
Pension Fund
0.83%
Sovereign Wealth Fund
0.72%
Bank and Trust
0.14%
Venture Capital
0.09%
Other
18.22%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
289
14.62M
81.83%
+655.24K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
2023Q3
343
11.50M
66.01%
-5.45M
2023Q2
356
11.96M
68.88%
-4.98M
2023Q1
359
12.15M
69.98%
-5.32M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Armistice Capital LLC
1.52M
8.48%
+364.00K
+31.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.48M
8.28%
-54.14K
-3.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.47M
8.23%
-33.13K
-2.20%
Mar 31, 2025
Soleus Capital Management, L.P.
1.13M
6.33%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
5.75%
+15.14K
+1.49%
Mar 31, 2025
Capitolis Liquid Global Markets LLC
693.10K
3.88%
+693.10K
--
Mar 31, 2025
State Street Global Advisors (US)
637.03K
3.56%
+256.52K
+67.41%
Mar 31, 2025
Acadian Asset Management LLC
565.04K
3.16%
+188.68K
+50.13%
Mar 31, 2025
Geode Capital Management, L.L.C.
411.17K
2.3%
+9.12K
+2.27%
Mar 31, 2025
CM Management, LLC
250.00K
1.4%
+7.50K
+3.09%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
0.75%
Zacks Small/Mid Cap ETF
0.6%
ALPS Medical Breakthroughs ETF
0.23%
SPDR S&P Biotech ETF
0.09%
iShares Micro-Cap ETF
0.07%
Vanguard US Momentum Factor ETF
0.06%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
Vanguard US Multifactor ETF
0.05%
Franklin US Small Cap Multifactor Index ETF
0.04%
Principal U.S. Small-Cap ETF
0.04%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil0.75%
Zacks Small/Mid Cap ETF
Anteil0.6%
ALPS Medical Breakthroughs ETF
Anteil0.23%
SPDR S&P Biotech ETF
Anteil0.09%
iShares Micro-Cap ETF
Anteil0.07%
Vanguard US Momentum Factor ETF
Anteil0.06%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.05%
Vanguard US Multifactor ETF
Anteil0.05%
Franklin US Small Cap Multifactor Index ETF
Anteil0.04%
Principal U.S. Small-Cap ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Datum
Art
Verhältnis
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
